Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Zi-Chun Yuan"'
Publikováno v:
BMC Complementary Medicine and Therapies, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Osimertinib is regarded as a promising third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for advanced non-squamous non-small cell lung cancer (NSCLC) patients who developed T790M. However the
Externí odkaz:
https://doaj.org/article/6996ef91c85145fe9062d1dc442c2a75
